

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Review Proposal Project

NICE Technology Appraisal No.163; Infliximab for acute exacerbations of ulcerative colitis

Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company/sponsor</u></p> <ul style="list-style-type: none"> • Janssen Biologics (infliximab) • Celltrion Healthcare (infliximab biosimilar) • Hospira UK Limited (infliximab biosimilar) • Samsung Bioepis UK (infliximab biosimilar) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Bladder and Bowel Community • Bowel Cancer UK • Colostomy Association • Crohn's and Colitis UK • IA: Ileostomy and Internal Pouch Group • Muslim Council of Britain • Ostomy Lifestyle • South Asian Health Foundation • Specialised Healthcare Alliance • Ulcerative Colitis UK <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Anaesthetists • Association of Coloproctology of Great Britain and Ireland • Association of Surgeons of Great Britain and Ireland • British Association of Urological Surgeons • British Geriatrics Society • British Society of Gastroenterology • Primary Care Society for Gastroenterology • Royal College of Anaesthetists • Royal College of General Practitioners • Royal College of Nursing 	<p><u>General commentators</u></p> <ul style="list-style-type: none"> • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare Products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Scottish Medicines Consortium <p><u>Comparators</u></p> <ul style="list-style-type: none"> • Novartis Pharmaceuticals (ciclosporin) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Cochrane Inflammatory Bowel Disease and Functional Bowel Disorders Group • CORE (Digestive Disorders Foundation) • MRC Clinical Trials Unit • National Institute for Health Research <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

<ul style="list-style-type: none">• Royal College of Pathologists• Royal College of Physicians• Royal College of Surgeons• Royal Pharmaceutical Society• Royal Society of Medicine• UK Clinical Pharmacy Association <p><u>Others</u></p> <ul style="list-style-type: none">• Department of Health• NHS England• NHS Harrow CCG• NHS Redbridge CCG• Welsh Government	
---	--

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to prepare a submission dossier, can respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Determination (FAD).

All non- company consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but are not asked to prepare a submission dossier. Commentators are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary).

All non-company organisations can nominate clinical or patient experts to present their personal views to the Appraisal Committee.